Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002 Aug 15;22(16):7006-15. PubMed Abstract

  
Comments on Paper and Primary News
  Comment by:  Eddie Koo, ARF Advisor
Submitted 22 August 2002  |  Permalink Posted 22 August 2002
  I recommend this paper

Interesting study to link rotenone's inhibition of complex I with PD pathology, i.e. alpha-synuclein and ubiquitin abnormalities and cell death.

View all comments by Eddie Koo

  Comment by:  Benjamin Wolozin, ARF Advisor (Disclosure)
Submitted 27 August 2002  |  Permalink Posted 27 August 2002
  I recommend this paper

Developing adequate cell culture models of synuclein aggregation has proved challenging, and this paper makes a significant step forward. It is curious that the process is so slow, given that the cells divide and likely don't exist in the same state (as one non-dividing cell) for 4 weeks. However, the slow kinetics of rotenone toxicity is consistent with prior studies with compound.

View all comments by Benjamin Wolozin

  Comment by:  Andre Delacourte
Submitted 29 August 2002  |  Permalink Posted 29 August 2002
  I recommend this paper

  Primary News: Novel Cell-Based Parkinson's Model Shows Promise

Comment by:  Ruth Perez
Submitted 30 August 2002  |  Permalink Posted 30 August 2002

The work by Tim Greenamyre, Todd Sherer, and colleagues provides a novel cellular model of chronic environmental toxin exposure that may well be relevant to Parkinson’s disease (PD). Although the authors did not use dopaminergic neurons (which they discuss in their paper) the data are nonetheless intriguing. Chronic low-dose rotenone treatment of a dividing neuronal cell line, SKN-MC, induced accumulation of endogenous α-synuclein protein in parallel with ubiquitin accumulation. Both soluble and insoluble α-synuclein protein levels increased, while α-synuclein mRNA did not. The data infer that rotenone contributes to α-synuclein protein stability. These findings are similar to studies by Dino Di Monte and colleagues (Manning-Bog et. al, 2002 ) in which non-transgenic mice expressing endogeonous levels of α-synuclein developed α-synuclein aggregates in substantia nigra neurons after treatment with the herbicide paraquat.

The relevance of both studies, in...  Read more


  Comment by:  Omar El-Agnaf
Submitted 3 September 2002  |  Permalink Posted 3 September 2002
  I recommend this paper

Very interesting study to link environmental toxins like rotenone with the development of PD. The development of cellular model of alpha-synuclein aggregation is important to understand the molecular mechanism of alpha-synuclein toxicity and screening for inhibitors of alpha-synuclein aggregation and toxicity.

View all comments by Omar El-Agnaf
  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:

Cultured SK-N-MC neuroblastoma cells were grown in MEM medium supplemented with 5 nM rotenone, a pesticide.

Synuclein and ubiquitin levels were determined by immunocytochemistry and protein dot blots. For immunocytochemistry, control and rotenone-treated cells were fixed and incubated with primary antibodies, polyclonal rabbit anti-alpha synuclein 1:100 (gift of Mark Cookson, Bethesda MD) and polyclonal rabbit against ubiquitin, for 24 hr, followed by 2nd biotinylated ab and ABC Elite kit.

For dot blots, control and rotenone-treated cells were lysed in lysis buffer (Promega, Madison, WI) containing 0.5 mg/ml benzamidine, 2 µg/ml aprotinin, 2 µg/ml leupeptin, 0.75 mM phenylmethylsulfonyl fluoride, 700 U/ml DNase I, and 1% mercaptoethanol. Primary antibodies were anti-alpha synuclein (1:400; Zymed, South San Francisco, CA) and anti-ubiquitin (1:500; Dako).

Determination of cytochrome c distribution and caspase-3 activation used immunofluorescence with the nuclei stained with Bisbenzamide. Cytochrome c was detected using a mouse monoclonal antibody (1:500; PharMingen, San Diego, CA). Active caspase-3 was detected using a polyclonal rabbit antibody (1:500; Cell Signaling, Beverly, MA). The fluorescent products were imaged with a Zeiss laser scanning microscope.

RT-PCR and Real-time PCR were used with primers for b-actin forward and reverse and a-synuclein forward and reverse. Primers were designed by Primer Express (Applied Biosystems)

For control and rotenone-treated cells, glutathione levels were assayed using a glutathione assay kit (Cayman Chemical Co.). Protein carbonyls were assayed with the Oxyblot protein oxidation detection kit(Intergen)which uses a fluorescent assay with anti-8-hydroxydeoxyguanosine (8-oxo-dG) antibodies (Trevigen, Gaithersburg, MD) to measure oxidative DNA damage. Apotosis was measured with Apoptag Plus fluorescein in-situ apoptosis detection kit (Intergen)and the cell death was measured with Sytox green dye (Molecular probes).

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad